Alliance to Market HPV Test

By HospiMedica staff writers
Posted on 10 Oct 2002

An agreement to jointly market an automated staining and imaging method of testing for human papillomarvirus (HPV) has been announced by ChromaVision Medical Systems, Inc. (San Juan Capistrano, CA, USA) and Ventana Medical Systems, Inc. (Tucson, AZ, USA).

The collaboration will market a newly developed test combining ChromaVision's ACIS image analysis systems with Ventana's reagents and automated staining platforms. Compared to existing HPV testing systems, the new method offers the pathologist direct visual interpretation of the cellular analyses, say the companies. The integrated testing system will be actively marketed to the firms' existing customers as well as to new laboratory customers.

"The HPV test is a natural extension of our technology and is complemented by Ventana's state-of-the-part products,” said Carl W. Apfelbach, president and CEO of ChromaVision. "The pairing of our technologies is geared at providing a level of accurate and precise information to physicians previously unattainable.”

Related Links:
ChromaVision
Ventana